SCHEMBL24089939

SCHEMBL24089939

O=c1c2cc(F)ccc2nc(Nc2ccccc2)n1-c1cncc(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 2/20 0.43
IDO2 Q6ZQW0 2/20 0.43
USP2 O75604 1/20 0.40
IDO1 P14902 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23064665 0.91 TDO2 (0.45) TDO2IDO2USP2IDO1
SCHEMBL24110953 0.90 TDO2 (0.42) TDO2IDO2IDO1
SCHEMBL23045329 0.88 TDO2 (0.45) TDO2IDO2USP2IDO1
SCHEMBL29623210 0.88 TDO2 (0.45) TDO2IDO2USP2IDO1
SCHEMBL23065096 0.88 TUBB4A (0.41) USP2
SCHEMBL23064661 0.86 CYP11B1 (0.42) TDO2IDO2USP2
SCHEMBL23064666 0.86 CYP11B1 (0.42) TDO2IDO2USP2IDO1
SCHEMBL23045334 0.86 TDO2 (0.50) TDO2IDO2USP2IDO1
SCHEMBL29623155 0.86 TDO2 (0.50) TDO2IDO2USP2IDO1
SCHEMBL24090095 0.86 PIK3CD (0.50) TDO2IDO2USP2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 US disclosed
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-05-12 US disclosed
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, CRKL TDO2 2059/4885IDO2 398/4885USP2 3443/4885
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, SLC26A3 TDO2 1774/4885IDO2 416/4885USP2 3548/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 TDO2 1774/4885IDO2 416/4885USP2 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.